KRAS and familial pancreatic carcinoma: In a genetically engineered mouse model of pancreatic cancer known as the iKras* mouse (p48-Cre; R26-rtTa IRES-EGFP; TetO-KrasG12D), characterized by pancreas-specific, inducible, and reversible expression of oncogenic KrasG12D (Kras*), the pancreas exhibited significantly elevated levels of IL-6 mRNA expression compared to the wild control group.